"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Descriptor ID |
D018358
|
| MeSH Number(s) |
C04.557.465.625.650 C04.557.580.625.650
|
| Concept/Terms |
Neuroendocrine Tumors- Neuroendocrine Tumors
- Neuroendocrine Tumor
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
|
Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".
Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".
This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 6 | 0 | 6 |
| 2015 | 5 | 2 | 7 |
| 2016 | 3 | 2 | 5 |
| 2017 | 4 | 0 | 4 |
| 2018 | 5 | 0 | 5 |
| 2019 | 8 | 1 | 9 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 0 | 3 |
| 2022 | 7 | 0 | 7 |
| 2023 | 10 | 0 | 10 |
| 2024 | 14 | 1 | 15 |
| 2025 | 8 | 0 | 8 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
All Together Now: Standardization of Nomenclature for Neuroendocrine Neoplasms across Multiple Organs. Clin Lab Med. 2026 Sep; 46(3):577-606.
-
Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. Clin Lab Med. 2026 Sep; 46(3):607-622.
-
Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study. Cancer Imaging. 2026 Aug 25; 26(1).
-
18F-FDOPA PET/CT for neuroendocrine tumors in multiple endocrine neoplasia type 1. Front Endocrinol (Lausanne). 2026; 17:1849746.
-
The Genetics and Screening of Gastroenteropancreatic Neuroendocrine Tumors and Adrenal Tumors. Surg Clin North Am. 2026 Aug; 106(4):555-569.
-
Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. Cancer Med. 2026 Apr; 15(4):e71809.
-
Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking. Surgery. 2026 Jan; 189:109762.
-
Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board. Target Oncol. 2025 Jul; 20(4):715-724.
-
Cause of death after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: a single center retrospective analysis. Eur J Surg Oncol. 2025 09; 51(9):110258.
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.